Thomas Gunderson, a director at Merit Medical Systems Inc (MMSI, Financial), has sold 18,157 shares of the company on March 4, 2024, according to a recent SEC filing. The transaction was executed at an average price of $76.03 per share, resulting in a total value of $1,380,055.71.
Merit Medical Systems Inc is a global company engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy.
Over the past year, Thomas Gunderson has sold a total of 18,157 shares of Merit Medical Systems Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of 10 insider sells and no insider buys over the same timeframe.
On the day of the insider's recent sale, shares of Merit Medical Systems Inc were trading at $76.03, giving the company a market capitalization of $4.394 billion. The price-earnings ratio of the company stands at 43.99, which is above the industry median of 27.57 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 1.01, indicating that Merit Medical Systems Inc is fairly valued based on its GF Value of $75.23. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which considers historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
